Brigatinib (Alunbrig®) accepted for use within NHS Scotland for treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer

Approved for patients previously not treated with an ALK inhibitor; offering an additional treatment choice in the therapeutic class of tyrosine kinase inhibitors for this indication.

Scottish Medicines Consortium